Zobrazeno 1 - 10
of 156
pro vyhledávání: '"Joy C Yang"'
Autor:
Pengfei Xu, Joy C. Yang, Bo Chen, Shu Ning, Xiong Zhang, Leyi Wang, Christopher Nip, Yuqiu Shen, Oleta T. Johnson, Gabriela Grigorean, Brett Phinney, Liangren Liu, Qiang Wei, Eva Corey, Clifford G. Tepper, Hong-Wu Chen, Christopher P. Evans, Marc A. Dall’Era, Allen C. Gao, Jason E. Gestwicki, Chengfei Liu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract N-Myc is a key driver of neuroblastoma and neuroendocrine prostate cancer (NEPC). One potential way to circumvent the challenge of undruggable N-Myc is to target the protein homeostasis (proteostasis) system that maintains N-Myc levels. Here
Externí odkaz:
https://doaj.org/article/7245d627558b40309015d3fca64f4865
Autor:
Bo Chen, William Murphy, Pengfei Xu, Chengfei Liu, Joy C Yang, Christopher Nip, Christopher P Evans, Leyi Wang, Jonathan EVan Dyke
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/0bf9acbb33b04596bda11be828834d66
Autor:
Shu Ning, Jinge Zhao, Alan P. Lombard, Leandro S. D’Abronzo, Amy R. Leslie, Masuda Sharifi, Wei Lou, Chengfei Liu, Joy C. Yang, Christopher P. Evans, Eva Corey, Hong-Wu Chen, Aiming Yu, Paramita M. Ghosh, Allen C. Gao
Publikováno v:
Communications Medicine, Vol 2, Iss 1, Pp 1-12 (2022)
Ning et al. report expression of a neural lineage gene signature in enzalutamide-resistant prostate cancer cells and datasets from patients with neuroendocrine prostate cancer. One of these genes, ARHGEF2, is associated with poor overall and disease-
Externí odkaz:
https://doaj.org/article/23a69cb8d6894a2792a756ea7fe5a961
Autor:
Bo Chen, William J Murphy, Xiong Zhang, Pengfei Xu, Chengfei Liu, Joy C Yang, Christopher Nip, Jonathan E Van Dyke, Hong-Wu Chen, Christopher P Evans
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
Background Emerging data suggest that patients with enzalutamide-treated prostate cancer with increased programmed death-ligand 1 (PD-L1) expression may benefit from anti-PD-L1 treatment. Unfortunately, the Phase III IMbassador250 clinical trial reve
Externí odkaz:
https://doaj.org/article/8f5213ee1f4342c4a2bb4d14ef4772c7
Autor:
Pengfei Xu, Joy C. Yang, Shu Ning, Bo Chen, Christopher Nip, Qiang Wei, Liangren Liu, Oleta T. Johnson, Allen C. Gao, Jason E. Gestwicki, Christopher P. Evans, Chengfei Liu
Publikováno v:
Pharmacological Research, Vol 189, Iss , Pp 106692- (2023)
Ubiquitin proteasome activity is suppressed in enzalutamide resistant prostate cancer cells, and the heat shock protein 70/STIP1 homology and U-box-containing protein 1 (HSP70/STUB1) machinery are involved in androgen receptor (AR) and AR variant pro
Externí odkaz:
https://doaj.org/article/0aa5beefd47948149ef46484906a60a3
Autor:
Pengfei Xu, Logan J. Wasielewski, Joy C. Yang, Demin Cai, Christopher P. Evans, William J. Murphy, Chengfei Liu
Publikováno v:
Biomedicines, Vol 10, Iss 8, p 1778 (2022)
Prostate cancer is one of the most common malignant tumors in men. Initially, it is androgen-dependent, but it eventually develops into castration-resistant prostate cancer (CRPC), which is incurable with current androgen receptor signaling target th
Externí odkaz:
https://doaj.org/article/3a3654ce0e524217895a066031c11c82
Autor:
Chengfei Liu, Wei Lou, Joy C. Yang, Liangren Liu, Cameron M. Armstrong, Alan P. Lombard, Ruining Zhao, Onika D. V. Noel, Clifford G. Tepper, Hong-Wu Chen, Marc Dall’Era, Christopher P. Evans, Allen C. Gao
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-16 (2018)
The AR-V7 isoform is associated with anti-androgen drug resistance in prostate cancer. Here, the authors show that AR-V7 protein stability is regulated by HSP70/STUB1 complex-mediated proteostasis which confers drug resistance in late stage prostate
Externí odkaz:
https://doaj.org/article/a5238e051d1c4725877bc665524a75c3
Autor:
Joy C. Yang, Pengfei Xu, Shu Ning, Logan J. Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin Gleave, Eva Corey, Allen C. Gao, Primo N. Lara Jr, Christopher P. Evans, Bruce D. Hammock, Chengfei Liu
Publikováno v:
Oncogene
Oncogene, vol 42, iss 9
Oncogene, vol 42, iss 9
Castration-resistant prostate cancer (CRPC) is the main driving force of mortality in prostate cancer patients. Among the parameters contributing to the progression of CRPC and treatment failure, elevation of the steroidogenic enzyme AKR1C3 and andro
Autor:
Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard, Leandro S. D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R. Leslie, Masuda Sharifi, Christopher P. Evans, Allen C. Gao
Publikováno v:
Molecular cancer therapeutics, vol 21, iss 10
Mol Cancer Ther
Mol Cancer Ther
The next-generation antiandrogen drugs such as enzalutamide and abiraterone extend survival times and improve quality of life in patients with advanced prostate cancer. However, resistance to both drugs occurs frequently through mechanisms that are i
Autor:
Allen C. Gao, Christopher P. Evans, Leandro S. D'Abronzo, Alan P. Lombard, Binhao Zou, Xiaomin Qiu, Liangren Liu, Wei Lou, Cameron M. Armstrong, Joy C. Yang, Chengfei Liu
Supplemental Figure 1: C4-2B parental and C4-2B MDVR tumors were processed and whole tumor lysates were extracted and subjected to western blot; Supplemental Figure 2: The KLK3 mRNA expression and PSA expression in C4-2B parental and C4-2B MDVR cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393fcc0da90d650d5db72e84a8be6a9e
https://doi.org/10.1158/1535-7163.22505649
https://doi.org/10.1158/1535-7163.22505649